Asciminib for Ph+ ALL: a step forward?
In this issue of Blood, Luskin et al present results of the first phase 1 trial combining asciminib, an allosteric BCR::ABL1 inhibitor, with the tyrosine k
Related Articles
Comprehensive characterization of MCL‐1 in patients with colorectal cancer: Expression, molecular profiles, and outcomes
MCL-1, an anti-apoptotic protein required for intestinal homeostasis, has been associated with chemoresistance in colorectal cancer. This study provides novel insights into the molecular profile…
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Tagitanlimab Plus Chemotherapy Receives Chinese Approval for Recurrent/Metastatic Nasopharyngeal Cancer
Tagitanlimab received marketing authorization from the Chinese NMPA for use with cisplatin and gemcitabine for patients with recurrent or metastatic NPC.
SHR-A1811 Maintains Efficacy, Safety in Pretreated HER2-Expressing/-Mutated Breast Cancer, Other Solid Tumors
An additional 1-year of follow-up confirmed the safety and activity of SHR-A1811 in HER2-expressing or -mutant solid tumors, including breast cancer.
IO-202 Plus Azacitidine Could Bring Long-Awaited Change in HMA-Naive CMML
Gabriel Mannis, MD, discusses the observed clinical activity and manageable safety profile of IO-202 combined with azacitidine in CMML.
Unique Questions Associated With the Increasing Prominence of Precision/Genomic Medicine in Routine Cancer Care
Maurie Markman, MD, delves into questions regarding precision medicine and genetic testing in cancer.
Daratumumab for maintenance in myeloma
In this issue of Blood, Badros and colleagues present the results from AURIGA, the first phase 3 randomized trial comparing daratumumab lenalidomide (DR) t
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study
Key PointsD-R maintenance improved MRD-negative conversion rate in patients with NDMM who were MRD-positive after transplant vs R maintenance.PFS favored D
Quantifying MM disease burden by BCMA?
In this issue of Blood, Ikeda and colleagues successfully demonstrated the utility of soluble B-cell maturation antigen (sBCMA) as a quantitative metric fo
Soluble B-cell maturation antigen levels for disease monitoring in oligosecretory and nonsecretory relapsed multiple myeloma
Key PointssBCMA correlates with %BMPC, total diffusion volume, circulating tumor cell, paraprotein levels, and changes in disease status in MM.sBCMA is use